Close Menu

NEW YORK – Fluidigm reported after the close of the market on Thursday that its second quarter revenues increased 7 percent year over year on continued strength in its mass cytometry product portfolio.

Despite the increased revenues, the market reacted negatively as Fluidigm missed top-line estimates and provided soft third quarter guidance on continued weakness in its microfluidics product sales. In Friday morning trading on the Nasdaq, Fluidigm's shares were down around 38 percent to $7.52.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.

ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.

The Washington Post reports that researchers are quickly analyzing the coronavirus that has been causing illness and sharing their findings.

In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.